BAYRY
The headline isn’t just earnings — it’s the balance sheet soap opera
Bayer’s latest update reads like one of those “good news, bad news, but mostly please look at the spreadsheet” moments. First-half sales climbed 3% on a currency- and portfolio-adjusted basis to €24.3 billion, with Crop Science and Consumer Health doing enough heavy lifting to offset some drag in pharma.
The business is holding up
That matters because Bayer has been trying to convince investors it’s more than just a legal-and-leverage headline machine. The company reiterated its full-year 2026 outlook, which is basically corporate-speak for: “We’re still on script, don’t panic.”
- Crop Science kept the growth engine humming
- Consumer Health also pulled its weight
- Parts of pharma were a little moody, as usual
Apollo’s €3 billion cameo
The real plot twist is the €3 billion equity investment from Apollo. Bayer also lowered its net financial debt target, which is music to investors’ ears if they’ve been staring at the company’s leverage like it’s a looming final boss.
Big picture: Bayer didn’t deliver a fireworks show, but it did give investors something better — a cleaner balance-sheet narrative plus stable guidance. In a world where “not worse” can count as progress, that’s not nothing.